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Abstract
Background: The efficacy of fixed-dose combinations (FDCs) in improving adherence and risk factor 
control for cardiovascular disease has not been reported consistently. Here, we compared adherence and 
efficacy between an olmesartan/rosuvastatin FDC and the usual regimen.
Methods: In this 6-month, open-label, randomized, active-control study, we screened 154 patients; of 
these, 150 were randomly assigned to receive either olmesartan/rosuvastatin FDC or the usual regi-
men with separate angiotensin receptor blockers and statins. In total, 135 patients completed the study 
(median age: 68 years; male: 68.9%). The primary outcome was patients’ adherence; the secondary 
outcomes were changes in blood pressure (BP) and lipid parameters. 
Results: During follow-up, adherence in both groups was high and similar between the groups 
(98.9% and 98.3% in the FDC and usual regimen groups, respectively, p = 0.328). Changes in systolic  
(–8 and –5 mmHg, respectively, p = 0.084) and diastolic BP (–5 and –2 mmHg, p = 0.092) did not dif-
fer significantly, although they were numerically greater in the FDC group. Changes in low-density lipo-
protein cholesterol (LDL-C) were greater in the FDC group (–13 and –4 mg/dL, respectively, p = 0.019),  
whereas changes in other lipid parameters were similar between the groups. The test drugs were well 
tolerated, showing no difference in safety between the groups.
Conclusions: Patients’ adherence was excellent and similar in the groups, whereas the reduction in the 
LDL-C level was greater in the FDC group. We provide comprehensive information on the adherence and  
efficacy of an FDC compared to the usual regimen in Korean patients with high cardiovascular risk. 
(Cardiol J)
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Introduction
Statins are currently the standard of care for 
cardiovascular prevention [1] and are commonly 
prescribed with antihypertensive agents for high-
-risk patients. The European guidelines classify 
patients with severe hypertension as a high-risk 
group, for whom active lipid-lowering therapy 
is recommended [2]. The American guidelines 
include blood pressure (BP) when calculating an 
individual’s cardiovascular risk using a pooled 
cohort equation [3]. Thus, the presence of hy-
pertension in a patient may increase the need for 
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use of combination or concomitant therapies with 
antihypertensives and lipid-lowering agents has 
increased in Korea [4]. 
Renin–angiotensin system (RAS) blockers are 
recommended for patients with ischemic heart 
disease plus hypertension, diabetes mellitus, heart 
failure, or chronic kidney disease. In addition, they 
are recommended for patients with multi-site vas-
cular diseases [5]. The use of RAS blockers is based 
on the results of studies, including the HOPE [6] 
and EUROPA [7] studies, which showed the ben-
efit of RAS blockers in secondary cardiovascular 
prevention. In addition, considering their efficacy 
and safety, angiotensin receptor blockers (ARBs) 
and statins are frequently co-prescribed in clinical 
trials and real-world practice [8, 9]. 
Patients’ adherence to a treatment regimen is 
known to be negatively affected by its complexity; 
thus, it can be improved by simplification of regi-
mens [10]. Previous studies compared a fixed-dose 
combination (FDC) of acetylsalicylic acid, a statin, 
and an angiotensin-converting enzyme inhibitor 
(ACEI) with a regimen of individual drugs. Several 
studies reported that an FDC can be helpful in 
increasing patients’ adherence [11–13]. Further-
more, a recent study in low- and middle-income 
countries found that an FDC is cost-effective in 
secondary cardiovascular disease prevention [14]. 
Conversely, the UMPIRE study demonstrated 
that an FDC was effective in controlling BP and 
low-density lipoprotein cholesterol (LDL-C) level 
[11]. However, several studies found no differen-
tial effect of FDCs and usual regimens in terms of 
control of risk factors [12, 13, 15]. Moreover, data 
on the effects of FDCs in East Asian patients are 
extremely limited.
Considering these results, the current FIXAR 
study aimed to compare the adherence of two 
groups of patients receiving an FDC consisting of 
olmesartan and rosuvastatin or the usual regimen. 
The usual regimen included individual drugs of any 
ARBs and statins that have comparable efficacy 
with that of the FDC. Secondly, we compared 
changes in BP and lipid parameters, including the 
LDL-C level. Drug tolerability in the study popula-
tion was also assessed. 
Methods
Study participants
Men and women aged 20–80 years who re-
quired antihypertensive and lipid-lowering thera-
pies were eligible for the study. Patients already 
under pharmacological treatment for hypertension 
and high blood cholesterol were initially screened. 
The need for pharmacological treatment was 
determined based on the guidelines of the 2013 
Korean Society of Hypertension [16] and the 
Korean Society of Lipid and Atherosclerosis [17]. 
Briefly, the inclusion criteria were as follows: pa-
tients with BP ≥ 140/90 mmHg or patients already 
under antihypertensive treatment. Furthermore, 
the patients had one of the following conditions: 
1) atherosclerotic cardiovascular disease; 2) dia-
betes, carotid artery stenosis with ≥ 50% luminal 
narrowing, or aortic aneurysm and LDL-C level 
≥ 100 mg/dL; 3) two or more cardiovascular risk 
factors and LDL-C level ≥ 130 mg/dL; or 4) no 
risk factors or one risk factor and LDL-C level 
≥ 160 mg/dL. The exclusion criteria were patients 
1) with uncontrolled hypertension (systolic BP 
≥ 180 mmHg or diastolic BP ≥ 110 mmHg); 2) with 
uncontrolled diabetes mellitus (hemoglobin A1c 
≥ 9% or fasting blood glucose ≥ 160 mg/dL); 3) with 
high-grade heart failure or clinically significant 
arrhythmia or who experienced cardiovascular or 
cerebrovascular events within 3 months of screen-
ing; and 4) with a history of chronic liver disease, 
chronic kidney disease (glomerular filtration rate 
< 60 mL/min/1.73 m2), or systemic inflammatory 
disease or those receiving systemic anti-inflam-
matory treatment; 5) with additional lipid-lowering 
agents other than the study drugs; as well as 6) 
pregnant or breast-feeding women or women with 
child-bearing potential not receiving contraception. 
All participants provided written informed consent. 
Study design
This was a 6-month, open-label, randomized, 
active-control study (ClinicalTrials.gov ID: 
NCT04061824). The institutional review board 
of Severance Hospital, Seoul, Korea approved the 
protocol (No. 4-2015-1122). At the screening visit, 
patients were interviewed regarding their medical 
history, and they underwent a physical examina-
tion and laboratory assessment. Participants who 
met the inclusion criteria were randomly assigned 
in a 1:1 ratio to receive one of the following two 
regimens: 1) an FDC of olmesartan/rosuvastatin 
(20 mg/5 mg, 20 mg/10 mg, 20 mg/20 mg, or 40 mg/ 
/20 mg); or 2) the usual regimen with ARBs and 
statins. The drug doses given to the participants 
of the FDC group were determined according to 
the potency of the ARBs and statins previously re-
ceived by the participants (i.e. before enrollment). 
After randomization, the participants were followed 
up at the end of the 3rd and 6th months for outcome 
evaluation. Although other medications, including 
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antiplatelet, anti-hypertensive, or anti-diabetic 
agents, were allowed in both groups, patients who 
changed drugs or doses during the study period 
were excluded from analysis. 
Adherence was estimated by direct measure-
ment via pill count. Patients were instructed to 
return all surplus medications at the follow-up visits. 
Adherence (%) was calculated as: the number of pills 
dispended/the number of pills prescribed × 100. 
In addition, BP was measured, and fasting blood 
samples were collected at randomization and at 
the end of the 6th month. BP was measured by the 
same person at a regular time using a validated elec-
tronic sphygmomanometer (HEM-7080 IT; Omron 
Healthcare, Kyoto, Japan). Laboratory parameters, 
including lipid profiles, were measured at these time 
points. Samples were analyzed within 4 h of collec-
tion by a local laboratory certified by the Korean 
Society of Laboratory Medicine. Tolerability was 
assessed from adverse event reports, history taking, 
physical examinations, and laboratory evaluations.
Statistical analysis
The primary outcome was drug adherence 
during the study period. The secondary outcomes 
included changes in systolic and diastolic BP as 
well as total cholesterol, triglyceride, high-density 
lipoprotein-cholesterol (HDL-C), and LDL-C lev-
els. A minimum of 62 participants per treatment 
group were required, assuming a power of 0.80, 
to determine the superiority of the FDC to the 
usual regimen in terms of the primary outcome. 
A 5 ± 10% difference in adherence between the 
groups was defined as significant. Assuming a 10% 
dropout rate, at least 68 individuals per group were 
recruited. The primary and secondary outcomes 
were analyzed in the population that underwent 
follow-up. Tolerability was assessed in all patients 
who were administered the study agents more 
than once. Differences in categorical variables 
between the groups were examined using the 
c2 test, whereas those in continuous variables were 
assessed using Student’s t-test. The paired t-test 
was used to evaluate differences before and after 
treatment in each group. Differences were consid-
ered significant at p values < 0.05 (two-sided). All 




In total, 154 patients were screened; of these, 
150 were subsequently randomized (Fig. 1). At 
screening, 4 patients did not meet the inclusion 
criteria and were excluded. Of the 150 randomized 
participants, 135 completed the study, whereas 
15 patients dropped out for the following reasons: 
9 due withdrawal of consent, 5 due to protocol 
violation, and 1 due to adverse events. The clinical 
characteristics of the patients are shown in Table 1. 
The median age was 68 years, and 93 (68.9%) 
154 patients screened
150 patients randomized
75 patients treated with FDC 75 patients treated with usual regimen
5 drop-out for withdrawal of consent 4 drop-out for withdrawal of consent
2 drop-out for protocol violation 3 drop-out for protocol violation
1 drop-out for adverse events 0 drop-out for adverse events
68 patients completed the study
Æ analyzed for adherence, BP, and laboratory variables
67 patients completed the study
Æ analyzed for adherence, BP, and laboratory variables
Figure 1. Study profile showing the numbers of patients who participated or dropped out; BP — blood pressure; 
FDC — fixed-dose combination.
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patients were male. Forty (29.6%) patients had 
diabetes mellitus, and 83 (61.5%) had a history of 
coronary artery disease. The median systolic BP 
was 129 mmHg, and the LDL-C level was 78 mg/dL 
at randomization. Demographic variables did not 
differ significantly between the groups. The doses 
of olmesartan and rosuvastatin used in the FDC 
group and ARBs and statins in the usual regimen 
group are shown in Table 2.
Primary and secondary outcomes 
At the 6-month follow-up, patients’ adherence 
to the regimens was not significantly different 
between the two groups (98.9% and 98.3% in 
the FDC and usual regimen groups, respectively, 
p = 0.328). The median change in systolic BP did 
not differ significantly between the two groups, 
although it was numerically greater in the FDC 
group than in the usual regimen group (–8 mmHg 
and –5 mmHg, respectively, p = 0.084). Similarly, 
the change in diastolic BP was similar in the two 
groups (–5 mmHg and –2 mmHg, respectively, 
p = 0.092). However, the median change in the 
LDL-C level was greater in the FDC group than in 
the usual regimen group (–13 mg/dL and –4 mg/dL, 
respectively, p = 0.019). The changes in the other 
lipid parameters were not different between the 
two groups (Table 3). 
Tolerability
The proportion of patients with adverse events 
in the FDC and usual regimen groups was similar 
(21 [31.3%] and 18 [26.4%] patients, respectively, 
p = 0.573). The test drugs were well tolerated during 
the study, and the number of patients with serious 
adverse events was not different between the groups 
(3 [4.4%] in both groups, p = 1.000). The relatively 
common adverse events observed in the study 
population included dizziness, upper gastrointes-
tinal symptoms, upper respiratory tract infection 
symptoms, headache, and myalgia, in order of 
frequency (Table 4).
Discussion
The major findings of our study included the 
following: 1) Patients’ adherence was higher than 
98% in the FDC and usual regimen groups and did 
not differ between the two groups. 2) The changes 
in systolic and diastolic BP were not significant-
ly different between the two groups, although 
they were numerically greater in the FDC group. 
3) The LDL-C level was reduced to a greater extent 
in the FDC group than in the usual regimen group. 
4) Tolerability of the study regimens in the two 
groups was similar during the study. Our study 
provides comprehensive information comparing 
Table 1. Clinical characteristics of the study participants.
FDC (n=67) Usual regimen (n = 68) P
Age [years] 68 (59, 73) 68 (60, 72) 0.923
Male 46 (68.6%) 47 (69.1%) 0.954
Medical history:
Hypertension 67 (100%) 68 (100%) 1.000
Diabetes mellitus 22 (32.8%) 18 (26.4%) 0.418
Hypercholesterolemia 62 (92.5%) 61 (89.7%) 0.563
Coronary artery disease 41 (61.1%) 42 (61.7%) 0.946
Peripheral artery disease 5 (7.4%) 3 (4.4%) 0.453
Body mass index [kg/m2] 24.8 (23.7, 26.8) 24.7 (23.3, 26.9) 0.956
Systolic BP [mmHg] 129 (119, 140) 129 (116, 140) 0.606
Diastolic BP [mmHg] 77 (69, 85) 75 (68, 84) 0.865
Lipid profile [mg/dL]:
Total cholesterol 153 (136, 168) 151 (128, 177) 0.904
Triglyceride 117 (91, 149) 114 (86, 171) 0.979
HDL-C 47 (40, 55) 47 (40, 56) 0.760
LDL-C 79 (65, 90) 76 (61, 98) 0.604
Data are presented as median (interquartile range) or number (%); FDC — fixed-dose combination; BP — blood pressure; HDL-C — high-
-density lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol
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the usual regimen and an FDC comprising an ARB 
and a statin in Korean patients with high cardio-
vascular risk. 
We found that patients’ adherence to the study 
regimens, including ARBs and statins, as well as 
the FDC, was higher than that in most previous 
studies. In a meta-analysis of 5 prior studies, the 
adherence rates were 93.0% and 92.8% in the FDC 
and control groups, respectively [18]. Similarly, 
a meta-analysis of 9 studies by Huffman et al. [19] 
reported a 15-month adherence of 86% and 65% 
for the FDC and control groups, respectively. Con-
Table 2. Doses of angiotensin receptor blockers (ARBs) and statins used in patients in the fixed-dose 
combination (FDC) and usual regimen groups, who completed the study.
FDC Number of patients 
(n = 67)
Usual regimen Number of patients 
(n = 68)
Olmesartan 20 mg/ 
/rosuvastatin 5 mg
12 (17.9) Equivalent regimens: 13 (19.1)
Candesartan 8 mg and atorvastatin 10 mg 3
Candesartan 8 mg and pravastatin 40 mg 1
Candesartan 8 mg and simvastatin 20 mg 1
Fimasartan 60 mg and pitavastatin 2 mg 1
Olmesartan 20 mg and atorvastatin 10 mg 1
Olmesartan 20 mg and rosuvastatin 5 mg 2
Telmisartan 40 mg and rosuvastatin 5 mg 2
Valsartan 80 mg and pitavastatin 2 mg 1
Valsartan 80 mg and pravastatin 40 mg 1
Olmesartan 20 mg/ 
/rosuvastatin 10 mg
25 (37.3) Equivalent regimens: 26 (38.2)
Candesartan 8 mg and rosuvastatin 10 mg 6
Fimasartan 30 mg and rosuvastatin 10 mg 1
Fimasartan 30 mg and simvastatin 40 mg 1
Losartan 50 mg and fluvastatin 80 mg 1
Olmesartan 20 mg and rosuvastatin 10 mg 9
Telmisartan 40 mg and rosuvastatin 10 mg 3
Valsartan 80 mg and pitavastatin 4 mg 1
Valsartan 80 mg and rosuvastatin 10 mg 3
Valsartan 80 mg and atorvastatin 20 mg 1
Olmesartan 20 mg/ 
/rosuvastatin 20 mg
19 (28.4) Equivalent regimens: 20 (29.4)
Candesartan 8 mg and atorvastatin 40 mg 1
Candesartan 8 mg and rosuvastatin 20 mg 1
Losartan 50 mg and atorvastatin 40 mg 1
Olmesartan 20 mg and rosuvastatin 20 mg 4
Telmisartan 40 mg and atorvastatin 40 mg 1
Telmisartan 40 mg and rosuvastatin 20 mg 2
Valsartan 80 mg and atorvastatin 40 mg 1
Valsartan 80 mg and rosuvastatin 20 mg 9
Olmesartan 40 mg/ 
/rosuvastatin 20 mg
11 (16.4) Equivalent regimens: 9 (13.2)
Candesartan 16 mg and rosuvastatin 20 mg 1
Losartan 100 mg and rosuvastatin 20 mg 1
Olmesartan 40 mg and rosuvastatin 20 mg 3
Telmisartan 80 mg and atorvastatin 40 mg 1
Valsartan 160 mg and atorvastatin 40 mg 1
Valsartan 160 mg and rosuvastatin 20 mg 2
Data are presented as number (%)
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Table 5. Adverse events.
FDC (n = 75) Usual regimen (n = 75) P
Patients with adverse events 21 (31.3%) 18 (26.4%) 0.573
Patients with serious adverse 
events
3 (4.4%) 3 (4.4%) 1.000
Frequency of each adverse event:
Dizziness 8 2
Upper GI symptoms 6 4




Skin problems 1 2
Minor bleeding 0 3
Others 9 15
Data are presented as number (%); FDC — fixed-dose combination; GI — gastrointestinal; URI — upper respiratory tract infection
Table 4. Primary and secondary outcome variables.
FDC (n = 69) Usual regimen (n = 73) P
Primary outcome variables:
Adherence [%] 98.9 (96.1, 100.0) 98.3 (95.6, 100.0) 0.328
Secondary outcome variables:
Systolic BP [mmHg] –8 (–18, 1) –5 (–15, 9) 0.084
Diastolic BP [mmHg] –5 (–12, 2) –2 (–10, 6) 0.092
Total cholesterol [mg/dL] –11 (–27, 1) –5 (–21, 8) 0.195
Triglyceride [mg/dL] 6 (–32, 37) 0 (–29, 21) 0.193
HDL-C [mg/dL] 1 (–4, 5) 1 (–5, 5) 0.878
LDL-C [mg/dL] –13 (–25, –1) –4 (–16, 7) 0.019
Data are presented as median (interquartile range); FDC — fixed-dose combination; BP — blood pressure; HDL-C — high-density lipoprotein 
cholesterol; LDL-C — low-density lipoprotein cholesterol
Table 3. Other anti-hypertensive agents used in patients in the fixed-dose combination (FDC) and usual 
regimen groups, who completed the study.
Regimen FDC (n = 67) Usual regimen (n = 68)
Beta-blocker 18 (26.9%) 22 (32.4%)
CCB 17 (25.4%) 14 (20.6%)
Diuretics 2 (3.0%) 2 (2.9%)
Beta-blocker and CCB 3 (4.5%) 5 (7.4%)
Beta-blocker and diuretics 0 (0%) 2 (2.9%)
CCB and diuretics 1 (1.5%) 1 (1.5%)
Beta-blocker, CCB, and diuretics 2 (3.0%) 1 (1.5%)
Others 1 (1.5%) 0 (0%)
Data are presented as number (%); CCB — calcium channel blocker
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versely, a recent study conducted in Iran revealed 
that the adherence to an FDC consisting of acetyl-
salicylic acid, a statin, and an ACEI or hydrochloro-
thiazide was 80.5% [20]. A study by Selak et al. [12] 
showed that the 12-month adherence to an FDC in-
cluding acetylsalicylic acid, statin, and an ACEI was 
81%, whereas that to the usual regimen was 46%. 
In addition, the 15-month adherence was 86% and 
65% in users of the FDC and usual regimen, respec-
tively, in the UMPIRE study [11]. In the Kanyini 
GAP study, the 18-month adherence was 70% and 
47% in the FDC and control groups, respectively 
[13]. Patients’ adherence to regimens can be af-
fected by the follow-up duration [21], patient’s age 
[22], underlying disease, number of drugs [22], 
and adverse events associated with the drugs. 
A meta-analysis by Webster et al. [21] revealed that 
adherence to a polypill was higher at earlier follow-
up time points than at later follow-up time points. 
The adherence in our study was higher than that 
in other studies, and it may be related to the short 
follow-up duration and relatively advanced age of 
the participants. Furthermore, we used ARBs as 
antihypertensive agents; thus, the higher safety 
profile of ARBs than that of ACEIs might have influ-
enced patients’ adherence. Although the reason for 
the high adherence rate in the usual regimen group 
in our study is not completely understood, it might 
be associated with the factors mentioned above.
In our study, the changes in the LDL-C level 
were greater in the FDC group than in the usual 
regimen group. A recent meta-analysis reported 
that achievement rates of BP and LDL-C level 
targets were higher in patients receiving a polypill 
than in those receiving the usual regimens [23]. 
In other studies, the reduction in BP and LDL-C 
level was also greater among FDC users [11]. 
In particular, patients who were undertreated or 
exhibited poor adherence at the baseline obtained 
greater benefit from FDCs [21, 24]. However, as 
mentioned in the introduction, FDCs or the usual 
regimen did not show significant differences in 
controlling the risk factors in many studies [12, 
13]. It is not clear why, in our study, the LDL-C 
level was reduced to a greater extent in the FDC 
group than in the usual regimen group, despite 
similar adherence in the two groups. We permit-
ted the use of diverse statins in the usual regimen 
group, whereas only rosuvastatin was used in the 
FDC group. Therefore, differences in individual 
responses to diverse statins in the usual regimen 
group might have partially caused the differential 
results. For example, statins such as atorvasta-
tin 20 mg and simvastatin 40 mg are considered 
to have lipid-lowering efficacy similar to that of 
rosuvastatin 10 mg. However, these regimens 
have been found to elicit slightly greater LDL-C 
reductions in some studies [25, 26]. Therefore, this 
modestly higher effect of rosuvastatin, compared 
to other statins with similar efficacy, might have 
induced greater LDL-C reduction in the patients 
receiving FDC of olmesartan/rosuvastatin in this 
study. However, further investigation is needed to 
fully explain this finding. 
In the current study, the rates of patients expe-
riencing adverse events were not different between 
the two groups, although it was numerically higher 
in the FDC group than in the other group. In an 
analysis of 9 prior studies, this rate was higher in 
the FDC group (30% and 24% in the FDC and usual 
regimen groups, respectively) [19]. These rates 
are consistent with those in our study. In addition, 
a study analyzing 9 randomized controlled trials 
revealed a modestly higher rate of adverse events 
in the FDC group [27]. However, the differential 
safety profile between FDCs and the usual regi-
men was not consistent in these previous studies. 
A meta-analysis involving 5 studies identified no 
significant difference in the rates of adverse events 
between the FDC and usual regimen groups [18]. 
Limitations of the study
Our study had some limitations. First, we did 
not fully assess concomitantly administered phar-
macological agents. Because a large proportion of 
the study population had coronary or peripheral 
artery disease, they might have received additional 
drugs, such as antiplatelet agents. Concomitant 
administration of additional drugs might have 
reduced the single-pill effect in the FDC group. 
Second, our study was conducted in a tertiary 
hospital, and most participants were well-treated 
at baseline. Thus, the adherence in the two groups 
was high, and the inter-group difference might have 
been minimized. Third, the follow-up duration was 
6 months, which is shorter than those in previous 
studies. This might have attenuated any potential 
difference in the primary and secondary outcomes 
between the two groups. Finally, our study was 
open label. Despite our best attempts to prevent 
it, potential bias caused by the study design cannot 
be completely ruled out. Nevertheless, it is note-
worthy that the current study was well performed 
to investigate our original study objective, and, 
for the first time, to our knowledge, we showed 
comparison data of the efficacy of an FDC and the 
usual regimen of hypertension in Korean patients 
with multiple risk factors. 
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Conclusions
In conclusion, patients’ adherence to the 
test regimens was excellent and similar in the 
two groups. The LDL-C level was reduced to 
a greater extent in the FDC group than in the usual 
regimen group, whereas changes in BP and other 
lipid parameters did not differ between the groups. 
Our study provides comprehensive information 
on the efficacy of an FDC compared with that of 
the usual regimen in Korean patients with high 
cardiovascular risk. 
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